Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Rapid Micro Biosystems (Nasdaq: RPID) reported preliminary unaudited revenue results for Q4 and full‑year 2025. Q4 2025 revenue ≈ $11.3M, up ~37% year‑over‑year, including placement of 16 new Growth Direct systems and validation of three customer systems.
Full‑year 2025 revenue is expected to be ≈ $33.6M, up ~20% year‑over‑year, with recurring revenue ≈ $17.8M, up ~15% year‑over‑year. The company placed 28 new Growth Direct systems in 2025 and has cumulatively placed 190 systems with 155 validated.
Results are preliminary and unaudited; final audited results and a webcast with 2026 outlook will be released in Q1 2026. The company will present at the J.P. Morgan Healthcare Conference on Jan 15, 2026.
Rapid Micro Biosystems (Nasdaq: RPID) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company investor relations website and will be archived for replay after the event.
Trinity Capital (Nasdaq: TRIN) announced a $45 million growth capital commitment to Rapid Micro Biosystems (Nasdaq: RPID) to support scaling of the Growth Direct platform and global commercial expansion.
The funding is designated to accelerate manufacturing scale, fund product cost reductions, improve service productivity, and drive gross margin expansion, with the stated goal of strengthening Rapid Micro's financial position and supporting long-term revenue growth and shareholder value.
Rapid Micro Biosystems (Nasdaq: RPID) reported third quarter 2025 results and updated guidance. Q3 revenue was $7.8 million, up 3% year-over-year, with recurring revenue +32% to $4.8 million and record consumable sales. The company posted a Q3 gross margin of 9% and a net loss of $11.5 million (EPS $0.26). Cash, equivalents and short-term investments were about $42 million as of September 30, 2025.
In October, the company received its largest multi-system order from a Top 20 global biopharma to place systems across North America, Europe and Asia Pacific. Rapid Micro raised full-year 2025 revenue guidance to at least $33.0 million, assuming at least 27 Growth Direct placements.
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the Stifel 2025 Healthcare Conference in New York. Management is scheduled for a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025 at 11:20 a.m. ET. A live webcast will be available on the company investor relations website and the webcast will be archived for replay after the event.
Rapid Micro Biosystems (Nasdaq: RPID) will release third quarter 2025 financial results before market open on Friday, November 7, 2025.
The company's management will host a webcast conference call at 8:30 a.m. ET on November 7, 2025 to discuss results; the live audio webcast is accessible on the company website and will be archived for replay.
Trinity Capital (NASDAQ:TRIN) has committed $45 million in growth capital to Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for microbial quality control in healthcare product manufacturing. The funding will support Rapid Micro's global expansion of their Growth Direct® platform and investments in manufacturing efficiency improvements.
The Growth Direct® platform enhances microbial testing processes by providing faster results, improved accuracy, increased operational efficiency, and enhanced data integrity. The capital will be used to scale operations, support commercial expansion, and drive gross margin growth through cost reduction and improved manufacturing efficiency.
Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for Tuesday, September 9, 2025, at 11:00 a.m. ET in New York. Investors can access the live webcast through the company's investor relations website at investors.rapidmicrobio.com, with a replay available after the event.
Rapid Micro Biosystems (NASDAQ:RPID) reported Q2 2025 financial results, with total revenue reaching $7.3 million, up 10% year-over-year. The company demonstrated strong performance with recurring revenue growing 15% to $4.4 million and service revenue increasing 18% to $2.5 million.
The company secured a significant $45 million term loan facility with Trinity Capital, with $20 million funded at closing. Despite a net loss of $11.9 million, RPID showed improvement in gross margin, reaching positive 4% compared to negative 3% in Q2 2024. The company placed four new Growth Direct systems and completed two system validations during the quarter.
RPID reaffirmed its full-year 2025 revenue guidance of at least $32.0 million. The company ended Q2 with approximately $32 million in cash, cash equivalents, short-term investments, and restricted cash.
Rapid Micro Biosystems (NASDAQ:RPID) has secured a $45 million term loan facility with Trinity Capital Inc. The five-year facility includes an initial $20 million drawn at closing, with potential access to an additional $25 million in subsequent tranches.
The loan features an initial 11.5% annual floating interest rate with a 36-month interest-only period, extendable based on future tranche drawdowns. The funding will support the company's Growth Direct system commercial expansion, manufacturing efficiencies, and product cost reduction initiatives, aiming to strengthen its path toward positive cash flow.
FAQ
What is the current stock price of Rapid Micro Biosystems (RPID)?
What is the market cap of Rapid Micro Biosystems (RPID)?
